Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

An Open-label,Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 18 to 59 Years.

Authors not listed

Sinovac Research and Development Co., Ltd. · 2021

Abstract

This study is an open-label phase Ⅳ clinical trial of the inactivated SARS-CoV-2 vaccine(CoronaVac)manufactured by Sinovac Research \& Development Co., Ltd. The purpose of this study is to evaluate the immunogenicity and safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 18 to 59 Years.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-10 MST

Cite this

APA
Anonymous. (2021). An Open-label,Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 18 to 59 Years. <em>Sinovac Research and Development Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT04962308
Vancouver
Anonymous. An Open-label,Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 18 to 59 Years. Sinovac Research and Development Co., Ltd.. 2021.
BibTeX
@misc{anon2021AnOpen, title = {An Open-label,Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 18 to 59 Years.}, author = {Anonymous}, journal = {Sinovac Research and Development Co., Ltd.}, year = {2021}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings